References
- Hutchison CA, Plant T, Drayson M, et al. Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease. BMC Nephrol. 2008;9:11
- Killingssworth LW, Warren BM. İmmunofixation for the Identification of Monoclonal Gammopathies. Beaumont, TX: Helena Laboratories; 1986
- Miettinen, TA, Kekki M. Effect of impaired hepatic and renal function and (131I) Bence Jones protein catabolism in human subjects. Clin Chim Acta. 1967;18:395–407
- Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med. 1967;126:207–221
- Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem. 2005;51:805–807
- Bradwell AR. Serum Free Light Chain Analysis. 6th ed. Birmingham: The Binding Site Ltd; 2010
- Gupta S, Comenzo RL, Hoffman BR, Fleisher M. National academy of clinical biochemistry guidelines for the use of tumor markers in monoclonal gammopathies. Section 3:K; 2005. Available at: http://www.aacc.org. Accessed June 1, 2015
- Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–224
- Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673–680
- Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell RA. Serum free light chains for monitoring multiple myeloma. Br J Hematol. 2004;126:348–354
- Solomon A, Waldmann TA, Fahey JL, McFarlane AS. Metabolism of Bence Jones proteins. J Clin Investig. 1964;43:103–117
- Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437–1444
- Levey AS, Stevens LA. Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622–627
- KDIGO 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:5–14
- Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1684–1690
- Nowrousian MR, Brandhorst D, Sammet C, Lellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Can Res. 2005;11:8706–8714
- van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol. 2006;533:319–326
- Solling K, Solling J, Romer FK. Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med Scand. 1981;209:473–477
- Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications. 2003;17:120–127
- Festa A, D’agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000;58:1703–1710
- Nezlin R. Human immunoglobulins. In: Nezlin R, Roald S, eds. The Immunoglobulins: Structure and Function. New York: Academic Press; 1998:95–100